Digestive Diseases

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Create a Registry for Patients at High-Risk for Pancreatic Cancer

   Rochester, Minn.

   This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC). and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.

2. A Study to Evaluate if New Tests (“biomarkers”) of Blood, Stool, Pancreas Cyst Fluid, or Pancreas Juice can be Used to Diagnose Malignant or Pre-malignant Changes in People with Pancreas Cysts

   Rochester, Minn.

   The goal of this protocol is to collect biospecimens in order to prospectively evaluate diagnostic and prognostic performance of MDMs for detection of advanced neoplasia in pancreatic cysts. 

3. A Study to Evaluate the Use of Confocal Laser Endomicroscopy as an IMaging Biomarker (CLIMB Study) for the Diagnosis of Pancreatic Cystic Lesions

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate EUS-nCLE as an imaging biomarker and PCL fluid DNA analysis as a molecular biomarker for the management of pancreatic cystic lesions (PCLs).

4. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to compare the effectiveness of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

5. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors

   Rochester, Minn.

   The purpose of this study is to determine the safety of VSV-IFNβ-NIS in combination with pembrolizumab, followed by expansion to examine effectiveness of combination therapy in patients with refractory Non-Small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC).

6. A Study to Evaluate Evacuation Mechanisms Using Advanced Brain Imaging

   Rochester, Minn.

   The objective of this study is to compare the central neural circuitry with fMRI (7T) in 30 asymptomatic healthy controls, 30 constipated patients without DD, and 30 constipated patients with DD at rest (functional connectivity analysis), during rectal distention to desire to defecate and urgency, and during evacuation. 

    

    

    

7. A Study to Develop a Registry for Outcomes and Predictors in Pouch-Related Disorders

   Rochester, Minn.

   The primary purpose of this study is to create a prospective registry of patients with pouch-related conditions to allow for longitudinal assessment of outcomes at 3, 6 and 12 months after a enrollment with a specific diagnosis (acute pouchitis, CADP, CARP, or CD of the pouch).

8. A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in 2 groups of patients with peritoneal carcinomatosis (PC), either due to primary ovarian, uterine, or gastric carcinoma (Arm 1) or to primary colorectal carcinoma (Arm 2), based on treatment-related adverse events reported by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.  

9. Effect of Cholecystokinin (CCK) on Gastroduodenal Activity in Humans

   Rochester, Minn.

   The purpose of this research study to compare the effects a hormone cholecystokinin (CCK) in the bloodstream in healthy people and in patients with rapid gastric emptying. CCK regulates (controls) the rate at which food empties from the stomach into the small intestine. We want to learn how CCK affects the activity of the stomach and small intestines in patients with rapid gastric emptying. We are also trying to learn if genes regulate the effects of CCK.

10. A Study to Evaluate the Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

    Rochester, Minn.

    The purpose of this study is to evaluate the effects of tradipitant relative to placebo in healthy volunteers:

    • Difference in fasting GV;
    • Difference in postprandial GV and in accommodation volume (that is, postprandial minus fasting gastric volumes);
    • Difference in gastric emptying (T1/2, emptying at 2h and emptying at 4h);
    • Volume to fullness (sensation of usual postprandial fullness) and maximum feeling of fullness (MTV).